Pfizer agreed to pay $14.5 million to settle allegations that the drug company illegally marketed its bladder-control drug Detrol.
Pfizer agrees to $14.5 million settlement
The settlement is the 10th lawsuit to address allegations that Pfizer improperly marketed Detrol, according to a Justice Department news release. The other suits were settled or dismissed in 2009 when the company agreed to pay $2.3 billion to resolve civil claims and criminal charges for several drugs.
Pfizer denied the allegations, according to the settlement agreement.
“We are pleased to report that the company has settled these qui tam allegations on favorable terms," Pfizer said in a statement. "This settlement allows Pfizer to avoid the cost and distraction of litigation and put this matter behind us."
The suit alleged that Pfizer illegally marketed Detrol for non-FDA-approved uses, including for male patients with benign prostatic hyperplasia and other conditions such as lower urinary tract symptoms and bladder outlet obstruction.
The settlement will be divided between state Medicaid programs, the federal government, and the two whistle-blowers. The whistle-blower suit had been filed in U.S. District Court in Boston, according to a news release from the Massachusetts attorney general's office.
“The United States is pleased that Pfizer has agreed to resolve the last of the pending cases that were not settled as part of the 2009 resolution and plea,” said Carmen Ortiz, U.S. Attorney for the District of Massachusetts, in a news release.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.